Breast Cancer Clinical Trials
Breast Cancer
Learn More About Breast Cancer
For general information on breast cancer (including risk factors, symptoms, diagnosis, and treatment) visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | ClinicalTrials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| SP-03-B101 | Breast Cancer | A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Combination with Exemestane in Patients with Advanced mTOR-sensitive solid tumors (HR+/HER2- Br Ca, RCC, NETs, TSC, HCC) | Targeted | Intravenous Everolimus. HR+ HER2- breast, HCC, RCC, NETs TSC- associated tumours | Open - Recruiting | Sapu Bioscience | ACTRN12625001083482 | Enquire Now |
| PTT-4256-01 | Breast Cancer | A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256 | Immunotherapy | Inhibitor of the pH-sensing G-protein-coupled receptor 65 | Open - Recruiting | Pathios Therapeutics Pty Ltd | NCT06634849 | Enquire Now |
| DM002001 | Breast Cancer | A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting MUC1 and HER3 | Open - Recruiting | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | NCT06751329 | Enquire Now |
| SL-28-FIH | Breast Cancer | A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours | Immunotherapy | IV allogeneic, non-genetically modified cell-based therapy | Open - Recruiting | Second Life Therapeutics Pty Ltd. | ACTRN12625001342404p | Enquire Now |
| ZE94-0605-0001 | Breast Cancer | Phase 1 Study of ZE94-0605 in Solid Tumors Who Have Exhausted All Treatment Options and Then With Expansion Into Two Dose Cohorts in Select Solid Tumor Patients | Targeted | Oral novel therapeutic targeting CDK2 in Cyclin E | Coming soon | Eilean Therapeutics | NCT07524140 | Enquire Now |